Abstract：
Concurrently acquired positron emission tomography and computed tomography (PET-CT) is an advanced imaging modality with diverse oncologic applications, including staging, therapeutic assessment, restaging and longitudinal surveillance. This series of six review articles focuses on providing practical information to providers and imaging professionals regarding the best use and interpretative strategies of PET-CT for oncologic indications in adult patients. In this fourth article of the series, the more common gynecological and adult genitourinary malignancies encountered in clinical practice are addressed, with an emphasis on Food and Drug Administration (FDA)-approved and clinically available radiopharmaceuticals. The advent of new FDA-approved radiopharmaceuticals for prostate cancer imaging has revolutionized PET-CT imaging in this important disease, and these are addressed in this report. However, [18F]F-fluoro-2-deoxy-d-glucose (FDG) remains the mainstay for PET-CT imaging of gynecologic and many other genitourinary malignancies. This information will serve as a guide for the appropriate role of PET-CT in the clinical management of gynecologic and genitourinary cancer patients for health care professionals caring for adult cancer patients. It also addresses the nuances and provides guidance in the accurate interpretation of FDG PET-CT in gynecological and genitourinary malignancies for imaging providers, including radiologists, nuclear medicine physicians and their trainees.
摘要：
同时获得的正电子发射断层扫描和计算机断层扫描（PET-CT）是一种先进的成像模式，具有多种肿瘤学应用，包括分期，治疗性评估,重新分类和纵向监测。这一系列六篇评论文章的重点是向提供者和成像专业人员提供有关PET-CT在成人患者肿瘤适应症中的最佳使用和解释策略的实用信息。在该系列的第四篇文章中，解决了临床实践中遇到的更常见的妇科和成人泌尿生殖系统恶性肿瘤，重点是食品和药物管理局（FDA）批准和临床可用的放射性药物。FDA批准的用于前列腺癌成像的新放射性药物的出现彻底改变了PET-CT在这种重要疾病中的成像，这些都在本报告中讨论。然而,[18F]F-氟-2-脱氧-d-葡萄糖（FDG）仍然是妇科和许多其他泌尿生殖系统恶性肿瘤的PET-CT成像的主要支柱。这些信息将作为PET-CT在妇科和泌尿生殖系统癌症患者临床管理中的适当作用的指南，为照顾成年癌症患者的医疗保健专业人员提供指导。它还解决了细微差别，并为影像学提供者准确解释妇科和泌尿生殖系统恶性肿瘤的FDGPET-CT提供了指导，包括放射科医生,核医学医生和他们的学员。
